Evaluation of endomorphin-1 on the activity of Na+,K+-ATPase using in vitro and in vivo studies

G. Horváth, Ahmad Agil, Gabriella Joo, I. Dobos, G. Benedek, Jose Manuel Baeyens

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The goal of this study was to investigate the effects of endomorphin-1 on Na+,K+-ATPase activity in mouse brain synaptosome in vitro, and its antinociceptive interaction with the Na+,K+-ATPase inhibitor ouabain. Endomorphin-1 (0.1 nM-10 μM) produced a concentration-dependent (EC50: 43.19 nM, CI: 23.38-65.71 nM, Emax: 25.86%, CI: 24.53-27.20%), naloxone-reversible increase of the synaptosomal Na+,K+-ATPase activity. The intrathecally (i.t.) administered endomorphin-1 (2-20 μg) produced a dose-dependent short-lasting increase in the tail-flick latency. Ouabain itself (1-1000 ng, i.t.) did not cause antinociception. Treatment with 10 ng ouabain significantly decreased the antinociceptive effect of 2 μg endomorphin-1, but none of the other combinations did significantly differ from the endomorhin-1-treated groups. These data indicate that endomorphin-1 increases the activity of Na+,K+-ATPase in vitro but this effect may play a weak role in the antinociception induced by intrathecal endomorphin-1.

Original languageEnglish
Pages (from-to)291-297
Number of pages7
JournalEuropean Journal of Pharmacology
Volume458
Issue number3
DOIs
Publication statusPublished - Jan 5 2003

Fingerprint

Ouabain
Synaptosomes
Naloxone
sodium-translocating ATPase
endomorphin 1
In Vitro Techniques
Tail
Brain

Keywords

  • Antinociception
  • Endomorphin-1
  • Na,K-ATPase
  • Ouabain
  • Tail-flick test

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Evaluation of endomorphin-1 on the activity of Na+,K+-ATPase using in vitro and in vivo studies. / Horváth, G.; Agil, Ahmad; Joo, Gabriella; Dobos, I.; Benedek, G.; Baeyens, Jose Manuel.

In: European Journal of Pharmacology, Vol. 458, No. 3, 05.01.2003, p. 291-297.

Research output: Contribution to journalArticle

@article{3fc5fd19230c48ffad271fc429ff896d,
title = "Evaluation of endomorphin-1 on the activity of Na+,K+-ATPase using in vitro and in vivo studies",
abstract = "The goal of this study was to investigate the effects of endomorphin-1 on Na+,K+-ATPase activity in mouse brain synaptosome in vitro, and its antinociceptive interaction with the Na+,K+-ATPase inhibitor ouabain. Endomorphin-1 (0.1 nM-10 μM) produced a concentration-dependent (EC50: 43.19 nM, CI: 23.38-65.71 nM, Emax: 25.86{\%}, CI: 24.53-27.20{\%}), naloxone-reversible increase of the synaptosomal Na+,K+-ATPase activity. The intrathecally (i.t.) administered endomorphin-1 (2-20 μg) produced a dose-dependent short-lasting increase in the tail-flick latency. Ouabain itself (1-1000 ng, i.t.) did not cause antinociception. Treatment with 10 ng ouabain significantly decreased the antinociceptive effect of 2 μg endomorphin-1, but none of the other combinations did significantly differ from the endomorhin-1-treated groups. These data indicate that endomorphin-1 increases the activity of Na+,K+-ATPase in vitro but this effect may play a weak role in the antinociception induced by intrathecal endomorphin-1.",
keywords = "Antinociception, Endomorphin-1, Na,K-ATPase, Ouabain, Tail-flick test",
author = "G. Horv{\'a}th and Ahmad Agil and Gabriella Joo and I. Dobos and G. Benedek and Baeyens, {Jose Manuel}",
year = "2003",
month = "1",
day = "5",
doi = "10.1016/S0014-2999(02)02813-3",
language = "English",
volume = "458",
pages = "291--297",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Evaluation of endomorphin-1 on the activity of Na+,K+-ATPase using in vitro and in vivo studies

AU - Horváth, G.

AU - Agil, Ahmad

AU - Joo, Gabriella

AU - Dobos, I.

AU - Benedek, G.

AU - Baeyens, Jose Manuel

PY - 2003/1/5

Y1 - 2003/1/5

N2 - The goal of this study was to investigate the effects of endomorphin-1 on Na+,K+-ATPase activity in mouse brain synaptosome in vitro, and its antinociceptive interaction with the Na+,K+-ATPase inhibitor ouabain. Endomorphin-1 (0.1 nM-10 μM) produced a concentration-dependent (EC50: 43.19 nM, CI: 23.38-65.71 nM, Emax: 25.86%, CI: 24.53-27.20%), naloxone-reversible increase of the synaptosomal Na+,K+-ATPase activity. The intrathecally (i.t.) administered endomorphin-1 (2-20 μg) produced a dose-dependent short-lasting increase in the tail-flick latency. Ouabain itself (1-1000 ng, i.t.) did not cause antinociception. Treatment with 10 ng ouabain significantly decreased the antinociceptive effect of 2 μg endomorphin-1, but none of the other combinations did significantly differ from the endomorhin-1-treated groups. These data indicate that endomorphin-1 increases the activity of Na+,K+-ATPase in vitro but this effect may play a weak role in the antinociception induced by intrathecal endomorphin-1.

AB - The goal of this study was to investigate the effects of endomorphin-1 on Na+,K+-ATPase activity in mouse brain synaptosome in vitro, and its antinociceptive interaction with the Na+,K+-ATPase inhibitor ouabain. Endomorphin-1 (0.1 nM-10 μM) produced a concentration-dependent (EC50: 43.19 nM, CI: 23.38-65.71 nM, Emax: 25.86%, CI: 24.53-27.20%), naloxone-reversible increase of the synaptosomal Na+,K+-ATPase activity. The intrathecally (i.t.) administered endomorphin-1 (2-20 μg) produced a dose-dependent short-lasting increase in the tail-flick latency. Ouabain itself (1-1000 ng, i.t.) did not cause antinociception. Treatment with 10 ng ouabain significantly decreased the antinociceptive effect of 2 μg endomorphin-1, but none of the other combinations did significantly differ from the endomorhin-1-treated groups. These data indicate that endomorphin-1 increases the activity of Na+,K+-ATPase in vitro but this effect may play a weak role in the antinociception induced by intrathecal endomorphin-1.

KW - Antinociception

KW - Endomorphin-1

KW - Na,K-ATPase

KW - Ouabain

KW - Tail-flick test

UR - http://www.scopus.com/inward/record.url?scp=12244297802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244297802&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(02)02813-3

DO - 10.1016/S0014-2999(02)02813-3

M3 - Article

C2 - 12504785

AN - SCOPUS:12244297802

VL - 458

SP - 291

EP - 297

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -